413 related articles for article (PubMed ID: 28324270)
1. Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.
Dhillon S
Target Oncol; 2017 Apr; 12(2):255-262. PubMed ID: 28324270
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
3. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
[TBL] [Abstract][Full Text] [Related]
4. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab for the treatment of indolent lymphoma.
Edelmann J; Gribben JG
Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab in follicular lymphoma.
Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
[TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.
Salles GA; Morschhauser F; Solal-Céligny P; Thieblemont C; Lamy T; Tilly H; Gyan E; Lei G; Wenger M; Wassner-Fritsch E; Cartron G
J Clin Oncol; 2013 Aug; 31(23):2920-6. PubMed ID: 23835715
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
Haukaas FS; Ohna A; Krivasi T
Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas.
Gabellier L; Cartron G
Ther Adv Hematol; 2016 Apr; 7(2):85-93. PubMed ID: 27054024
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia.
Hoy SM
Drugs; 2015 Feb; 75(3):285-96. PubMed ID: 25586272
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
16. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S; Winderlich M; Dirnberger-Hertweck M; Korolkiewicz R; Blum KA
Ann Oncol; 2018 May; 29(5):1266-1272. PubMed ID: 29444231
[TBL] [Abstract][Full Text] [Related]
17. Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
[TBL] [Abstract][Full Text] [Related]
20. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
Trotman J; Cheah CY; Marlton P; Opat S
Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
